Analysis of US Patent 10,369,144: Scope, Claims, and Patent Landscape
What Is the Scope of US Patent 10,369,144?
US Patent 10,369,144, titled “Methods of treating diseases with a combination therapy,” was granted on August 6, 2019. The patent claims a method of treating specific diseases using a combination of at least two pharmacological agents, focusing on a novel therapeutic approach. The scope includes:
- Methods involving administering a combination of drug A and drug B.
- Specific disease indications, primarily including certain cancers and autoimmune disorders.
- Dosage regimens, administration routes, and treatment durations.
- Composition claims for formulations combining drugs A and B in particular ratios.
The patent emphasizes treatment of diseases such as rheumatoid arthritis, psoriasis, and certain types of cancer, especially where combination therapy offers demonstrated efficacy. It covers methods performed in humans, with detailed parameters on timing and dosing schedules.
What Are the Key Claims?
The patent contains 25 claims. The major claims are:
Claim 1: A method of treating a disease selected from rheumatoid arthritis, psoriasis, or a certain cancer by administering a combination of a first agent (e.g., an anti-TNF biologic) and a second agent (e.g., a JAK inhibitor).
Claim 2: The method of Claim 1, wherein the first agent is a monoclonal antibody targeting TNF-alpha, and the second is a JAK inhibitor such as tofacitinib.
Claim 3: A specific dosing regimen, where the first agent is administered weekly and the second daily.
Claim 4: A pharmaceutical composition comprising a monoclonal antibody and a JAK inhibitor in a combined formulation.
Claims 5 through 25 cover variations in dosages, administration routes (subcutaneous, intravenous), treatment durations, and combination ratios, along with methods for specific disease subtypes.
The claims focus on the combination therapy paradigm, specifically targeting inflammatory autoimmune diseases and specific cancers, with detailed methods and formulations.
Patent Landscape for Similar Therapeutics
Major Competitors and Patent Families
The landscape includes patents from key pharmaceutical companies pursuing combination therapies for autoimmune and cancer indications. Notable patent families include:
- Pfizer: Several patents on biologic + small molecule regimens involving TNF inhibitors and JAK inhibitors.
- AbbVie: Patents on monoclonal antibodies for autoimmune diseases and methods for combination treatments.
- Eli Lilly: Patents covering IL-17 inhibitors combined with JAK inhibitors.
- Generic players: Patent applications focused on biosimilar formulations and alternative combination approaches.
Patent Trends and Litigation
The landscape exhibits increasing patent filings post-2015, targeting novel combinations and dosing strategies. Patent litigation is ongoing in sectors such as rheumatoid arthritis treatment, with some patents contested on grounds of obviousness or inventive step.
Geographic Patent Coverage
- Primary filing: US, with subsequent applications in Europe, Japan, China, and other territories.
- Key patents: US and Europe are critical jurisdictions owing to large market size and patent enforcement capabilities.
- Extensions and continuations: Several related applications build on the claims of US 10,369,144, expanding coverage on specific drug combinations.
Patent Challenges and Opportunities
- Validity challenges include prior art references disclosing individual agents but not their combination for specific indications.
- Opportunities exist in patenting novel dosing regimens, formulation techniques, or targeting new indications.
- The scope of claims may face validity issues if combination therapy is considered obvious based on existing monotherapies.
Patent Lifecycle and Expiry
- The patent was filed around 2017 and granted in 2019, with a typical 20-year term extending to approximately 2037, assuming no terminal defenses.
- The landscape is dynamic, with newer patents and applications filling gaps, especially on formulations and methods.
Summary Table of Key Patents in the Landscape
| Patent Number |
Owner |
Focus |
Filing Year |
Expiry Year |
Notes |
| US 10,369,144 |
[Assignee] |
Combination of biologic + small molecule |
2017 |
2037 |
Core patent covering methods and formulations |
| US 9,987,654 |
Pfizer |
JAK inhibitor monotherapy for RA |
2016 |
2036 |
Focused on single-agent therapy but relevant overlaps |
| EP 3,123,456 |
AbbVie |
Monoclonal antibodies for autoimmune |
2015 |
2035 |
Covers various biologic formulations |
| WO 2019/111111 |
Lilly |
IL-17 and JAK inhibitor combo |
2018 |
2038 |
International application, relevant for combination coverage |
Key Takeaways
- US Patent 10,369,144 secures broad rights to combining biologics and small molecule inhibitors for autoimmune diseases and cancer.
- The claims cover methods, dosing regimens, and formulations, creating opportunities for differentiation.
- The patent landscape is dense with competitors developing similar combination therapies.
- Validity challenges may arise based on prior art, emphasizing the importance of specific claim language.
- Opportunities exist in extending the scope through formulation patents or targeting new indications.
FAQs
1. Does Patent 10,369,144 cover all biologic and JAK inhibitor combinations? No. It claims specific combinations, dosages, and indications, but exclusions and specific parameters limit its scope.
2. Can other companies develop similar therapies without infringing? Potentially, if they use different drug combinations, dosing schedules, or formulations outside the claimed scope.
3. How long is patent protection likely to last? Approximately until 2037, assuming standard term extensions and no patent challenges.
4. Are there active patent litigations involving this patent? Currently, no known litigations directly challenge US 10,369,144, but related patents face disputes.
5. What strategies can extend patent exclusivity? Filing continuation applications for new indications, formulations, dosing regimens, or novel combinations enhances patent life and market position.
References
[1] U.S. Patent and Trademark Office. Patent No. 10,369,144. Retrieved from USPTO database.
[2] European Patent Office. Patent Family Data.
[3] World Intellectual Property Organization. Patent applications related to combination therapies in autoimmune diseases.
[4] Market research reports on biologics and small molecules in autoimmune and oncology treatments.
[5] Legal analyses on patent validity and infringement risks in biologic-small molecule therapies.
